Skip to content
VuFind
  • Login
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
Advanced
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Save to List
  • Permanent link
Cover Image

Saved in:
Bibliographic Details
Main Authors: Kazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, Fujimasa Tada, Hideko Ohama, Hidenori Toyoda, Satoshi Yasuda, Toshifumi Tada, Kazunari Tanaka, Kunihiko Tsuji, Ei Itobayashi, Akemi Tsutsui, Koichi Takaguchi, Michitaka Imai, Toru Ishikawa, Takeshi Hatanaka, Satoru Kakizaki, Atsushi Naganuma, Yoshihide Ueda, Tomomitsu Matono, Hideyuki Tamai, Junpei Okamura, Hironori Tanaka, Yutaka Yata, Akiko Wakuta, Masatoshi Kudo, Takashi Kumada
Format: Artículo Open Access
Published: Wiley 2025
Subjects:
Hepatology Research
Online Access:https://onlinelibrary.wiley.com/doi/10.1111/hepr.70070
Tags: Add Tag
No Tags, Be the first to tag this record!
  • Holdings
  • Description
  • Table of Contents
  • Comments
  • Similar Items
  • Staff View

Internet

https://onlinelibrary.wiley.com/doi/10.1111/hepr.70070

Similar Items

  • Ablation‐Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma
    by: Kazuya Kariyama, et al.
    Published: (2026)
  • Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct‐acting antiviral agents
    by: Hideko Ohama, et al.
    Published: (2024)
  • Effect of Butyrate‐Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab
    by: Kazuhiro Nouso, et al.
    Published: (2026)
  • Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma
    by: Atsushi Naganuma, et al.
    Published: (2025)
  • Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients
    by: Takeshi Hatanaka, et al.
    Published: (2024)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs